Azivet

100 mg/ml Azithromycin + 10 mg/ml Lidocaine hydrochloride

Sterile solution for intramuscular, subcutaneous injection for cattle, sheep, goats, pigs, dogs

COMPOSITION PER ML

Azithromycin……..….... 100 mg.
Lidocaine hydrochloride…….... 10 mg.
Excipient (propylene glycol), solvent (dimethylacetamide). Clear colourless to yellow solution free from visible particles.

INDICATIONS FOR USE

For the treatment of bacterial infections of the respiratory, alimentary and urinary tract, skin and soft tissues in cattle, sheep, goats, pigs, dogs caused by organisms sensitive to azithromycin. Azivet is also used in cases of erysipelas, dysentery, necrobacillosis and mycoplasma infection.

DOSAGE AND ADMINISTRATION

For intramuscular or subcutaneous injection.
- Cattle, sheep, goats, pigs: 1 ml per 20-40 kg body weight administered by intramuscular injection once daily for 2 days. The volume administered per injection site should not exceed 7 ml. Repeat course of the treatment if required.
- Dogs: 1 ml per 10 kg body weight administered by intramuscular or subcutaneous injection once daily for 3-5 days. The volume administered per injection site should not exceed 5 ml.

PHARMACOLOGICAL PROPERTIES

Azivet is active against aerobic Gram-positive bacteria (Enterococcus spp., Listeria monocytogenes, Staphylococcus spp., Streptococcus spp., Erysipelothrix rhusiopathiae), aerobic Gram-negative bacteria (Actinobacillus pleuropneumoniae, Actinobacillus lignieresii, Acinetobacter spp., Bordetella spp., Campylobacter spp., Enterobacter spp., Escherichia coli, Haemophilus spp., Moraxella spp., Pasteurella spp., Proteus spp., Pseudomonas spp., Salmonella spp., Serratia spp.), anaerobic bacteria (Clostridium perfringens, Fusobacterium necrophorum), Mycoplasma spp., Chlamydia spp., Rickettsia spp., Treponema hyodysenteriae.
Azithromycin is an azalide, a member of a subclass of macrolide antibiotics with broad spectrum of action against both intracellular and extracellular organisms. It is bacteriostatic and can demonstrate concentration-dependent bactericidal activity due to higher intracellular concentrations. By binding to the 50S ribosomal subunit, azithromycin avoids the translocation of peptide chains.
Azithromycin exerts anti-inflammatory, immunomodulatory, mucoregulatory actions; these properties are associated with modulating effect on phagocytosis, chemotaxis, neutrophil apoptosis.
Lidocaine is a local anesthetic agent. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Antagonism with calcium ions is possible.
Following parenteral administration, azithromycin is quickly absorbed and distributed to all tissues of the body reaching peak blood concentrations in 30-60 minutes after injection and remains within the therapeutic range for 72 hours. In the lungs and macrophages, the therapeutic concentration is maintained for 120 hours following the injection.
Higher concentrations are demonstrated in bronchopulmonary tissues. Due to accumulation in phagocytes, the product is selectively distributed to the foci of septic inflammation, where its high concentrations are created.
Azithromycin is metabolised mainly through demethylation.
Following parenteral administration, lidocaine is also rapidly absorbed. Lidocaine has an initial half-life of 60-90 minutes. The excretion of lidocaine occurs via the liver.
Azivet is excreted as metabolites in the urine and bile.

CONTRAINDICATIONS

Do not use in the case of known hypersensitivity to the active substances. If allergy reactions occur, treatment should be discontinued and antihistamine and symptomatic therapy should be undertaken as appropriate.
Do not use in lactating animals producing milk for human consumption.

ADVERSE REACTIONS

Administration of Azivet may cause transient pain reactions at the injection site that can persist for a few days.

DRUG INTERACTIONS

Concurrent administration of heparin, cardiac glycosides, anesthetics, hypnotics, beta blocking agents (propranolol, bisoprolol), antiarrhythmic medications (amiodarone, verapamil, quinidine, ajmalin), bactericidal antibiotics is not allowed.
Tetracyclines and amphenicols increase the effect of azithromycin.
This product must not be mixed with other veterinary medicinal products in the same syringe.

WITHDRAWAL PERIODS

Cattle, sheep, goats (meat): 45 days.
Pigs (meat): 35 days.
Milk: Not authorised for use in lactating animals producing milk for human consumption.

SPECIAL WARNINGS

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

USER WARNINGS

Care should be taken to avoid accidental self-injection. In the case of accidental self-injection, seek medical advice immediately. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations. Wash hands after use.

STORAGE CONDITIONS AND SHELF LIFE

Store in the original package between 5°C to 25°C, protected from light and moisture.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after first opening the container: 28 days (aseptic precautions should be observed).
Do not use this veterinary product after the expiry date which is stated on the label.
Keep out of the reach and sight of children.

MARKETING PACKAGING

Azivet is marketed in glass vials of 10, 50, 100, 200, 250, 400, 450, 500 ml.

MANUFACTURER

Belekotechnika Ltd, 9 Promyshlenny lane, 222823 Svisloch, Pukhovichi region, Minsk area, the Republic of Belarus.
Approved: May 13, 2020.